Pulmonary arterial hypertension (PAH) Program in Pharmaceutical Benefits Schedule (PBS) 012-18051131

This document outlines details of PBS-subsidised ambrisentan, bosentan, epoprostenol, iloprost, macitentan, riociguat, selexipag, sildenafil, and tadalafil for patients with pulmonary arterial hypertension (PAH). Monotherapy, dual therapy, and triple therapy treatment options are available.

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial 1 (new patients) PB070 form	Written Electronic S100: ambrisentan bosentan epoprostenol iloprost macitentan riociguat sildenafil tadalafil	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes
Initial 2 (change)	Telephone Electronic S100: ambrisentan bosentan epoprostenol iloprost macitentan riociguat sildenafil tadalafil	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes
Continuing	Telephone Electronic S100: ambrisentan bosentan epoprostenol iloprost macitentan riociguat sildenafil tadalafil	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes
Cessation	Telephone Electronic S100: bosentan 62.5mg	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes

Pulmonary arterial hypertension (PAH) - dual or triple therapy quick reference (excluding selexipag)

Table 2

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial 1 (excluding selexipag, for previously untreated patients) PB303 form	Written Electronic S100: Dual therapy a combination of either: one ERA and one PDE-5i ambrisentan bosentan macitentan with: sildenafil tadalafil or one ERA and one prostanoid ambrisentan bosentan macitentan with: epoprostenol iloprost or one PDE-5i and one prostanoid sildenafil tadalafil with: epoprostenol iloprost Triple therapy a combination of: one ERA, one PDE-5i and one prostanoid ambrisentan bosentan macitentan with: epoprostenol iloprost and: sildenafil tadalafil	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes
Initial 2 (excluding selexipag, for previously treated)	Telephone Electronic S100: Dual therapy a combination of either: one ERA and one PDE-5i ambrisentan bosentan macitentan with: sildenafil tadalafil or one ERA and one prostanoid ambrisentan bosentan macitentan with: epoprostenol iloprost Triple therapy a combination of: one ERA, one PDE-5i and one prostanoid ambrisentan bosentan macitentan with: epoprostenol iloprost and: sildenafil tadalafil	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes
Initial 3 (excluding selexipag, for change of treatment)	Telephone Electronic S100: Dual therapy a combination of either: one ERA and one PDE-5i ambrisentan bosentan macitentan with: sildenafil tadalafil or one ERA and one prostanoid ambrisentan bosentan macitentan with: epoprostenol iloprost or one PDE-5i and one prostanoid sildenafil tadalafil with: epoprostenol iloprost Triple therapy a combination of: one ERA, one PDE-5i and one prostanoid ambrisentan bosentan macitentan with: epoprostenol iloprost and: sildenafil tadalafil	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes
Continuing (dual or triple therapy, excluding selexipag)	Telephone Electronic S100: Dual therapy a combination of either: one ERA and one PDE-5i ambrisentan bosentan macitentan with: sildenafil tadalafil or one ERA and one prostanoid ambrisentan bosentan macitentan with: epoprostenol iloprost or one PDE-5i and one prostanoid sildenafil tadalafil with: epoprostenol iloprost Triple therapy a combination of: one ERA, one PDE-5i and one prostanoid ambrisentan bosentan macitentan with: epoprostenol iloprost and: sildenafil tadalafil	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes
Cessation	Telephone Electronic S100: bosentan 62.5mg	No	OPA	Must be treated and prescribed by a: physician with expertise in the management of PAH	Yes

Pulmonary arterial hypertension (PAH) - triple therapy quick reference (including selexipag)

Table 3

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial (titration)

Telephone

Electronic

S100:

selexipag

OPA

Must be treated and prescribed by a:

physician with expertise in the management of PAH

Yes

Initial (after dose titration)

Telephone

Electronic

S100:

selexipag

OPA

Must be treated and prescribed by a:

physician with expertise in the management of PAH

Yes

Initial/Continuing

Telephone

Electronic

S100:

ambrisentan

bosentan

macitentan

sildenafil

tadalafil

Note: the initial authority application for selexipag must be approved prior to the authority approval for treatment with the second and/or third agents as triple therapy or dual therapy in lieu of triple therapy

OPA

Must be treated and prescribed by a:

physician with expertise in management of PAH

Yes

Continuing

Telephone

Electronic

S100:

selexipag

OPA

Must be treated and prescribed by a:

physician with expertise in management of PAH

Yes

Operational Information

Pulmonary arterial hypertension (PAH) Program in Pharmaceutical Benefits Schedule (PBS) 012-18051131

On this page:

Pulmonary arterial hypertension (PAH) - monotherapy quick reference

Pulmonary arterial hypertension (PAH) - dual or triple therapy quick reference (excluding selexipag)

Pulmonary arterial hypertension (PAH) - triple therapy quick reference (including selexipag)